Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lindsey H. M. te Brake"'
Autor:
Carlijn H. C. Litjens, Laurens F. M. Verscheijden, Elin M. Svensson, Petra H. H. van den Broek, Hedwig van Hove, Jan B. Koenderink, Frans G. M. Russel, Rob E. Aarnoutse, Lindsey H. M. te Brake
Publikováno v:
Antibiotics, Vol 12, Iss 4, p 702 (2023)
Linezolid is used off-label for treatment of central nervous system infections. However, its pharmacokinetics and target attainment in cranial cerebrospinal fluid (CSF) in tuberculous meningitis patients is unknown. This study aimed to predict linezo
Externí odkaz:
https://doaj.org/article/1cda5fe5ffa44c3da3aedc061453a16f
Autor:
Vera E Bukkems, Coca Necsoi, Carmen Hidalgo Tenorio, Coral Garcia, Irene Alba Alejandre, Fabian Weiss, John S Lambert, Astrid van Hulzen, Olivier Richel, Lindsey H M te Brake, Eric van der Meulen, David Burger, Deborah Konopnicki, Angela Colbers
Publikováno v:
Clinical Infectious Diseases, 75, 623-629
Clinical Infectious Diseases, 75, 4, pp. 623-629
Clinical Infectious Diseases, 75, 4, pp. 623-629
Background Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with human immunodeficiency virus (HIV), but there are limited data on TAF use
Autor:
Lindsey H M, Te Brake, Veronique, de Jager, Kim, Narunsky, Naadira, Vanker, Elin M, Svensson, Patrick P J, Phillips, Stephen H, Gillespie, Norbert, Heinrich, Michael, Hoelscher, Rodney, Dawson, Andreas H, Diacon, Rob E, Aarnoutse, Martin J, Boeree
Publikováno v:
The European Respiratory Journal
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Background Accumulating data indicate that higher rifampicin doses are more effective and shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 7- and 14-day early bactericidal activity (EB